Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...244245246247248249250251252253254...10661067»
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Glucocorticoid-Regulated Kinase CAMKIγ in the Central Amygdala Controls Anxiety-like Behavior in Mice. (Pubmed Central) -  Oct 28, 2022   
    Here, we find that restraint-induced stress and the GR agonist dexamethasone robustly increase the expression of Camk1g in neurons of the amygdalar nuclei in the mouse brain...Mice with bilateral amygdala-specific Camk1g knock-down showed increased anxiety-like behaviors in the light-dark box, and an increase in freezing behavior after fear-conditioning, but normal spatial working memory during exploration of a Y-maze. Thus, we confirm that Camk1g is a neuron-specific GR-regulated transcript, and show that it is specifically involved in behaviors related to anxiety, as well as responses conditioned by aversive stimuli.
  • ||||||||||  carfilzomib / Generic mfg.
    Journal, Real-world evidence:  Carfilzomib's Real-World Safety Outcomes in Korea: Target Trial Emulation Study Using Electronic Health Records. (Pubmed Central) -  Oct 28, 2022   
    The KRd regimen were related with significantly increased risks of dyspnea (adjusted HR (aHR) 2.27, 95% confidence interval (CI) 1.24-4.16), muscle spasm (aHR 5.12, 95% CI 1.05-24.9) and thrombocytopenia (aHR 1.84, 95% CI 1.10-3.06). Although the severities were low, carfilzomib has many side effects in treating RRMM; hence, findings on the patterns of its adverse events could lead to both effective and safe use of KRd therapy in real-world settings.
  • ||||||||||  dexamethasone / Generic mfg., prednisone / Generic mfg., hydrocortisone / Generic mfg.
    Clinical, Review, Journal:  Pregnancy and Prenatal Management of Congenital Adrenal Hyperplasia. (Pubmed Central) -  Oct 28, 2022   
    Several advances, however, have been made, especially in terms of fertility and reproduction. This review aims to present the most recent scientific and real-world updates on pregnancy and prenatal management of CAH, with the presentation of various clinical scenarios and specific case-by-case recommendations.
  • ||||||||||  dexamethasone / Generic mfg.
    Preclinical, Journal:  Reactivation of Coccidioidomycosis in a Mouse Model of Asymptomatic Controlled Disease. (Pubmed Central) -  Oct 28, 2022   
    B6D2F1 mice asymptomatically infected with C. posadasii strain 1038 were immunosuppressed with dexamethasone (DXM) in drinking water...Histopathologically, DXM stop mice did not redevelop controlled granulomas by sacrifice, though T-cells were densely scattered throughout the lesions. This demonstrates a mouse model suitable for further study to understand the immunologic components responsible for maintenance control of coccidioidomycosis.
  • ||||||||||  dexamethasone injection / Generic mfg.
    Biomarker, Journal:  Optical Coherence Tomography Reflectivity in Foveal Cysts: A Novel Biomarker for Early-Response Prediction of Diabetic Macular Edema Treated with Dexamethasone. (Pubmed Central) -  Oct 28, 2022   
    This study investigated spectral-domain optical coherence tomography (OCT) biomarkers to predict short-term anatomical improvement for diabetic macular edema (DME) after dexamethasone (DEX) injection in intravitreal anti-vascular endothelial growth factor (anti-VEGF) non-responders...ODN and ODR showed negative correlations with CMT changes (R = -0.546, p = 0.002 and R = -0.436, p = 0.014, respectively). Higher OCT reflectivity in the foveal cystoid space was associated with a lesser decrease in CMT after DEX injection in anti-VEGF non-responders, suggesting the usefulness of this parameter in predicting short-term CMT responses after DEX injection.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  The Nutraceutical Genistein-Lycopene Combination Improves Bone Damage Induced by Glucocorticoids by Stimulating the Osteoblast Formation Process. (Pubmed Central) -  Oct 28, 2022   
    Femurs obtained from the Sham group were used for osteoblasts extraction; they were then incubated with dexamethasone (DEX) for 24 h to be then treated with lycopene or genistein or the association of lycopene and genistein for an additional 24 h. Treatments with lycopene and genistein restored the impaired mineralization of cells observed following DEX treatment and stimulated osteoblast differentiation by increasing the depressed expression of bALP and RUNX2 (p < 0.0001)...The combined treatment of genistein and lycopene improved the bone damage induced by glucocorticoids and significantly restored the normal architecture of bones as well as adequate interconnectivity of bone trabeculae, thus increasing bone mineral density parameters. The obtained data demonstrated that genistein and lycopene but in particular their association might prevent GC's adverse effects, thus stimulating bone formation and reducing bone resorption, improving bone structure and microarchitecture, through different molecular pathways, such as the Wnt/β-catenin and the Nrf-2 signaling.
  • ||||||||||  Journal:  Preliminary Study of κ-Carrageenan Based Membranes for Anti-Inflammatory Drug Delivery. (Pubmed Central) -  Oct 28, 2022   
    The obtained membranes were characterized by FTIR, TG/DTG and UV-VIS methods and the data collected following these methods indicated success in terms of the incorporation of the active substance, as well as the high thermal stability in the temperature range 37-100 °C of both the matrices of membrane types, as well as the membranes with the drug incorporated. All the studies carried out led to the conclusion that within all the membranes the anti-inflammatory substances were intact and, thus we can say that these membranes can be used for transdermal administration of the studied anti-inflammatory substances.
  • ||||||||||  Darzalex (daratumumab) / J&J
    Review, Journal:  Axillary Lymphadenopathy as an Initial Presentation of Systemic Amyloidosis: A Case Report and Literature Review. (Pubmed Central) -  Oct 28, 2022   
    Patient is in remission for 1 year, at the time of submission of this report. Therefore, we conclude (1) systemic amyloidosis presenting as an isolated lymph node enlargement is rare, (2) a structured systemic work up is imperative for early diagnosis and proper management of amyloidosis, when there is an index of suspicion, and (3) use of novel therapeutic options such as CD38 + antibody (daratumumab) and stem cell transplant have positive impact on disease outcomes.
  • ||||||||||  prednisolone / Generic mfg., prednisone / Generic mfg.
    Journal:  Dutch guideline to prevent perioperative pulmonal complications: how is the adherence? (Pubmed Central) -  Oct 28, 2022   
    There are also notable differences between the vision of pulmonologists and the anesthesiologists. Further research is needed to solidify the guideline, anticipating aforementioned compliance barriers to achieve better implementation.
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion date, Trial primary completion date, Surgery:  MIDCAB (Mid-Calf Block) for Foot Surgery (clinicaltrials.gov) -  Oct 28, 2022   
    P4,  N=20, Recruiting, 
    Furthermore, assessment of inflammation by use of MRI after 6 g of IVMP has a potential role in predicting recurrence. Trial completion date: Nov 2022 --> Apr 2023 | Trial primary completion date: Sep 2022 --> Apr 2023
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma. (Great HAll) -  Oct 27, 2022 - Abstract #ISHL2022ISHL_102;    
    The treatment protocol consisted of 2 cycles of chemotherapy according to Nivo40-BeGEV scheme (vinorelbine 20 mg/m2 on day 1 dexamethasone 20 mg/m2 on days 1–5 gemcitabine 800 mg/m2 on days 1 and 4 bendamustine 90 mg/m2 on days days 2 and 3 nivolumab 40 mg IV on day 0) with further assessment of response by PET/CT. The combination of nivolumab at a fixed dose of 40 mg with chemotherapy BeGEV has demonstrated high efficacy and the absence of severe adverse eventes in patients with r/r cHL.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Integrative analysis of macrophage ribo-Seq and RNA-Seq data define glucocorticoid receptor regulated inflammatory response genes into distinct regulatory classes. (Pubmed Central) -  Oct 27, 2022   
    Glucocorticoids such as dexamethasone (Dex) are widely used to treat both acute and chronic inflammatory conditions...Overrepresentation pathway analysis combined with STRING protein network analysis and manual functional exploration, identified these genes to encode immune effectors and immunomodulators that contribute to macrophage-mediated immunity and to the maintenance of macrophage-mediated immune homeostasis. Further research into the translational regulatory network underlying the GR anti-inflammatory response could pave the way for the development of novel immunomodulatory therapeutic regimens with fewer undesirable side effects.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Journal:  Controlled Delivery of Corticosteroids Using Tunable Tough Adhesives. (Pubmed Central) -  Oct 27, 2022   
    Tissue adhesive alginate-polyacrylamide tough hydrogels were recently demonstrated to serve as an extended-release system for the corticosteroid triamcinolone acetonide...A first technical exploration of a TADDS shelf-life concept was performed using lyophilization, where lyophilized TADDS were physically stable and the bioactive integrity of released triamcinolone acetonide was demonstrated. Given the tunability of properties, the TADDS are a suggested technology platform for controlled drug delivery.
  • ||||||||||  dexamethasone / Generic mfg., lenalidomide / Generic mfg.
    Journal:  Rosai-Dorfman-Destombes disease with a misleading laryngeal presentation (Pubmed Central) -  Oct 27, 2022   
    Simultaneously, NGS analysis of the laryngeal lesion showed a mutation in the MAP2K1 gene, in accordance with the diagnosis. The patient was treated with revlimid and dexamethasone for 6 months, with complete remission, and is currently undergoing maintenance treatment with revlimid.
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Journal:  Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA. (Pubmed Central) -  Oct 27, 2022   
    P3
    Longer median treatment duration and more Grade ≥ 3 treatment-emergent adverse events occurred in the Isa versus control arms in ICARIA-MM (36.9 vs 8.4 weeks; 85.7 % vs 70.0 %) and IKEMA (41.9 vs 29.9 weeks; 100.0 % vs 57.1 %); however, Isa did not increase the percentage of patients with fatal events or drug discontinuation. Isa-Pd or Isa-Kd is a potential new treatment option and partially overcomes the poor prognosis associated with soft-tissue plasmacytomas in relapsed and/or refractory multiple myeloma.
  • ||||||||||  dexamethasone / Generic mfg., nystatin oral / Generic mfg.
    Journal:  Novel Meso-Benzothiazole-Substituted BODIPY-Based AIE Fluorescent Rotor for Imaging Lysosomal Viscosity and Monitoring Autophagy. (Pubmed Central) -  Oct 27, 2022   
    As a comparison, its analogue 2 directly linking with the phenyl group showed no viscosity-responsive or AIE properties. Therefore, for the first time, we reported a meso-benzothiazole-BODIPY-based fluorescent rotor with AIE and lysosomal viscosity-responsive properties in nervous cells, which was further applied in monitoring autophagy, and this work thus could provide an innovative strategy for the design of potential AIE and viscosity-responsive probes.
  • ||||||||||  dexamethasone / Generic mfg.
    Retrospective data, Journal:  Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals. (Pubmed Central) -  Oct 27, 2022   
    Severe disease was defined as hospitalization within 14 days of a positive SARS-CoV-2 diagnostic test and either blood oxygen level of less than 94%, receipt of supplemental oxygen or dexamethasone, mechanical ventilation, or death within 28 days...In this nationwide, retrospective cohort of predominantly male US Veterans, we identified risk factors associated with severe disease despite vaccination. Findings could be used to inform outreach efforts for booster vaccinations and to inform clinical decision-making about patients most likely to benefit from preexposure prophylaxis and antiviral therapy.
  • ||||||||||  Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
    Clinical guideline:  ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts. (Pubmed Central) -  Oct 27, 2022   
    Fluticasone furoate/vilanterol trifenatate (FF/Vi) is one such example of an ICS/uLABA...This consensus paper also sheds light upon the appropriate reliever to be used along with FF/Vi in Asthma and the utilization of FF/Vi-based triple therapy in OADs. Expert recommendations mentioned in this paper will serve as guidance to pulmonologists as well as consultant physicians who are involved in providing care to OAD patients and will help them weigh the various factors that need to be taken into account while prescribing ICS/uLABA combination.
  • ||||||||||  Buventol Easyhaler (salbutamol dry-powder inhaler) / Orion Corp, Bufomix Easyhaler (budesonide/formoterol dry powder inhaler) / Orion Corp
    Trial completion date, Trial primary completion date:  EASYRELIEF: Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (clinicaltrials.gov) -  Oct 27, 2022   
    P4,  N=180, Recruiting, 
    Trial primary completion date: Mar 2022 --> Jan 2023 Trial completion date: Sep 2022 --> May 2023 | Trial primary completion date: Sep 2022 --> May 2023